Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012:8:299-305.
doi: 10.2147/VHRM.S22589. Epub 2012 May 14.

Critical evaluation of the efficacy and tolerability of azilsartan

Alberto R De Caterina  1 , Andrew R Harper, Florim Cuculi
Affiliations
Review

Critical evaluation of the efficacy and tolerability of azilsartan

Alberto R De Caterina et al. Vasc Health Risk Manag. 2012.

Erratum in

  • Vasc Health Risk Manag. 2012;8:443-5

Abstract

Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.

Keywords: angiotensin receptor blocker; azilsartan medoxomil; hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The renin-angiotensin-aldosterone system.
See this image and copyright information in PMC

References

    1. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761–2788. - PubMed
    1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746–2753. - PubMed
    1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–223. - PubMed
    1. Guilbert JJ. The world health report 2002 – reducing risks, promoting healthy life. Educ Health (Abingdon) 2003;16(2):230. - PubMed
    1. Lawes CM, Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–1518. - PubMed

MeSH terms